Kornimate/medical-research-clean huggingface dataset:
ai models to predict thyroid cartilage invasion in laryngeal carcinoma

Conditions: Laryngeal Carcinoma; Thyroid Cartilage

Summary: this retrospective study was to develop and verify ct-based ai model to preoperatively predict the thyroid cartilage invasion of laryngeal cancer patients, so as to provide more accurate diagnosis and treatment basis for clinicians. in addition, the researchers investigated the prediction of survival outcomes of patients by the above optimal models.

laryngeal squamous cell carcinoma (lscc), as one of the most common head and neck tumors, is the eighth leading cause of cancer-associated death worldwide. the treatment decisions has a profound impact on both tumor control and functional prognosis of lscc patients. and these decisions are primarily based on tumor staging, with the invasion of the thyroid cartilage serving as a crucial determinant. consequently, the presence of thyroid cartilage invasion indicates an advanced stage (t3 or t4) diagnosis for the lscc patients. for patients without thyroid cartilage invasion, partial laryngectomy may be considered to preserve laryngeal function. however, for patients with advanced laryngeal carcinoma and thyroid cartilage invasion extending beyond the larynx, total laryngectomy is often necessary to completely remove the tumor and extend survival time. therefore, accurate assessment of thyroid cartilage invasion is vital for treatment decision-making and prognosis evaluation for lscc patients.

Eligibility criteria:
inclusion criteria: 1. availability of complete clinical data 2. surgery-proven or biopsy-proven diagnosis of laryngeal squamous cell carcinoma 3. ct examination performed within 2 weeks before surgery exclusion criteria: 1. patients who received preoperative chemotherapy or radiation therapy 2. ct images with significant artifacts 3. patients with tumor recurrence

Keywords: radiomics deep learning
sleeve gastrectomy versus one-anastomosis gastric bypass: randomized trial

Conditions: Morbid Obesity

Summary: hormonal changes after sg and oagb involve alterations in the levels of many enteric hormones, among these hormones are ghrelin and glucagon-like peptide-1 (glp-1). ghrelin is an orexigenic hormone that stimulates food intake and has a documented role in the development of obesity. while ghrelin levels decrease significantly after sg as the fundus, which is the main source of that hormone, is completely removed, they tend to increase after oagb glp-1 plays an important role in glucose homeostasis via affecting food intake and satiety. it enhances insulin secretion, stimulates the proliferation and growth of pancreatic beta cells, inhibits food and water intake, and promotes satiety. some studies reported that both oagb and sg are followed by increased glp-1 levels. we conducted this randomized study to compare sg and oagb with regards to weight loss, comorbidity resolution, changes in ghrelin and glp-1 hormones, and complications.


Eligibility criteria:
inclusion criteria: * adult patients of both genders with morbid obesity (defined as bmi \> 40 kg/m2 or \> 35 kg/m2 with at least one associated comorbidity) were included. patients who underwent previous surgery for morbid obesity were also included. exclusion criteria: * patients ageing more than 60 years * patients with endocrine disorders * patients with psychiatric disorders that influence perception of the study protocol * patients unfit for general anesthesia.
survey on patients after childbearth following bariatric surgery

Conditions: Bariatric Surgery Status in Childbirth; Puerperal Depression

Summary: women with a history of bariatric surgery may face various difficulties during pregnancy and puerperal time. therefore it is assumed the prevalence of mental health disorders might be higher than in average women during and after pregnancy. this could possibly lead to an unsatisfying weight progress and therapeutic non-adherence. these factors shall be observed in the study in order to characterize this special cohort of participants.

women following bariatric surgery are included at least 6 months after childbirth to evaluate retrospectively pregnancy and puerperal time. for mental health issues questionnaires, a structured clinical interview (scid) and a psychological interview give an insight to past and present status. in order to evaluate weight progress and nutrient deficiencies routine follow-up care data of bariatric surgery is screened. in order to assess the course of pregnancy and child development data is extracted from pregnancy and child's examinations reports. furthermore medication adherence, quality of life and sleep are registered by questionnaires.

Eligibility criteria:
inclusion criteria: * 18 years of age * status following bariatric / metabolic surgery due to indication criteria * childbirth after bariatric / metabolic surgery, at least 6 months ago * written informed consent exclusion criteria: -
the duchenne registry

Conditions: Duchenne Muscular Dystrophy; Becker Muscular Dystrophy

Summary: the duchenne registry is an online, patient-report registry for individuals with duchenne and becker muscular dystrophy and carrier females. the purpose of the registry is to connect duchenne and becker patients with actively recruiting clinical trials and research studies, and to educate patients and families about duchenne and becker care and research. at the same time, the duchenne registry is a valuable resource for clinicians and researchers in academia and industry, allowing access to de-identified datasets provided by patients and their families-information that is vital to advances in the care and treatment of duchenne. the duchenne registry is a member of the treat-nmd neuromuscular network.

the duchenne registry (previously duchenneconnect) was created in 2007 by parent project muscular dystrophy (ppmd), with assistance from the nih, the cdc, and emory genetics. in early 2011, ppmd alone began financing the registry's operation and maintenance, and is the sole guardian of the duchenne registry and its material. questions may be addressed to the duchenne registry coordinators at telephone 888-520-8675 or coordinator@duchenneregistry.org. the duchenne registry coordinators are certified genetic counselors who are available to answer questions regarding the registration process, genetic testing and counseling, and clinical trials and research studies.

Eligibility criteria:
inclusion criteria: * diagnosis of duchenne or becker muscular dystrophy; manifesting female carriers and asymptomatic female carriers also included in registry. exclusion criteria: * diagnosis of any other type of muscular dystrophy (including limb-girdle muscular dystrophy).

Keywords: duchenne becker muscular dystrophy
comparison between intravenous hydrocortisone and ondansetron in prevention of post spinal anesthesia hypotension

Conditions: Post Spinal Anaesthesia Hypotension

Summary: the purpose of this study is to assess and contrast the effectiveness of intravenous ondansetron and intravenous hydrocortisone in avoiding spinal anesthesia-induced hypotension.

according to the medication investigated in this study, patients will be divided into three equal groups (40 each). patients will receive one of the following 15 minutes before spinal anesthesia: 1. hydrocortisone 100 mg (h group) 2. ondansetron 8 mg (o group) 3. an identical volume of sterile distilled water (control group) (c group). spinal anesthesia will be performed under complete aseptic conditions with the patient seated, a 25-gauge quincke spinal needle is used to administer 3.5 ml of a 0.5% hyperbaric bupivacaine together with 25 micrograms of fentanyl at the l3-l4 or l4-l5 level. patients will lie supine with slight head elevation after the intrathecal injection is finished. intravenous infusion of 500 ml normal saline over the initial post spinal 30 minutes. sensory level and motor block will be verified. heart rate (hr), systolic (sbp), diastolic (dbp) and mean blood pressure (mbp) will be measured every 5 min for 30 min during which the patient remains in the supine position with no application of torniquet. if the map drops by 20% below baseline or the systolic blood pressure falls below 90 mmhg, hypotension is recorded and will be treated with intravenous incremental doses of 5 mg ephedrine. if the heart rate drops below 50 beats per minute, bradycardia is recorded, and atropine 0.5 mg will be administered intravenously. if ephedrine or atropine were used, only data from before their administration would be analyzed. the doses of ephedrine and atropine needed will be recorded. nausea, vomiting and shivering will be recorded when occur till the end of operation.

Eligibility criteria:
inclusion criteria: 1. asa i and ii (physical status according to american society of anesthesiologists). 2. patients aged 21 years or more. 3. either sex. 4. abdominal and lower limb operations. exclusion criteria: 1. patient refusal. 2. hemodynamic instability 3. hematological diseases, bleeding or coagulation abnormality. 4. local skin infection and sepsis at site of spinal anesthesia 5. neuromuscular diseases (as myopathies, myasthenia gravies...) 6. preexisting neurological deficit or psychiatric diseases. 7. known intolerance to the study drugs. 8. patients already receiving any of the study drugs. 9. diabetic patient.
the effect of granulocyte colony stimulating factor (g-csf) on myocardial function after acute anterior myocardial infarction, a prospective double blind randomized placebo controlled study

Conditions: Myocardial Infarction

Summary: the investigators applied g-csf to patients 2 weeks after acute anterior mi and successful pci to evaluate the efficacy and safety of g-csf in improving myocardial function as cytokine which improve inflammation and mobilize stem cells from bone marrow for regeneration of myocardium.

ten patients in the treatment group and 10 patients in the control group were enrolled in this prospective, randomized, double blinded study. two weeks after myocardial infarction that was accompanied by successful recanalization and stent implantation, the patients of the treatment group received 10 μg/kg body weight per day (divided bid) g-csf subcutaneously for treatment duration of maximum 5.0 days. in both groups, ejection fraction was evaluated with echocardiography and cardiac scan (gated spect method) 10 days after myocardial infarction and after 6 months. tei index was measured by echocardiography. results: no severe side effects of g-csf treatment were observed. ejection fraction determined by cardiac scan increased in the treatment group from 0.428 to 0.462 and from 0.470 to 0.496 in the control group but there was no significant improvement of left ventricular ejection fraction when the g-csf treated group was compared to the controls (p=0.821 for cardiac scan and p=0.705 for echocardiography). changes in tei index was not significant in the treatment group (p=0.815) however it reached significant level in the control group (p=0.005), respectively.

Eligibility criteria:
inclusion criteria: * first anterior myocardial infarction. * low systolic ventricular function. exclusion criteria: * bleeding tendency * contraindication to g-csf * cardiogenic shock * hemodynamic instability * hepatic or renal disease * multivessel disease

Keywords: g-csf myocardial infarction
safety and efficacy of intranasal administration of niclosamide (uni91103) in adults with asymptomatic or mild covid-19

Conditions: Covid19

Summary: the purpose of this study is to assess the safety and efficacy of uni91103 intranasal spray for treatment of coronavirus disease 2019 (covid-19) in asymptomatic or mildly symptomatic adults.


Eligibility criteria:
inclusion criteria: * subject is male or female aged ≥45 and \<80 years * subject is tested to confirm infection with sars-cov-2 on a sample taken within 3 days before randomization * subject is either without symptoms or has 1 or more of the following symptoms: stuffy or runny nose, sore throat, loss of taste, loss of smell, headache. none of the symptoms should have been present \>5 days. exclusion criteria: * subject has an underlying condition that may interfere with intranasal administration of the imp (e.g., chronic ulcers in the nose). * subject has symptoms suggesting engagement of the lower respiratory tract or a systemic engagement * subject has an active or acute infection other than sars-cov-2 * subject has another member of the same household recruited to this study
evaluation of an on-demand humidifier on neuromuscular patients requiring mechanical ventilation

Conditions: Neuromuscular Diseases

Summary: monocenter study to determine and evaluate the optimal amount of humidification doses delivered by the on-demand humidification system in neuromuscular patients requiring home mechanical ventilation. the patient's perception will be monitored with subjective as well as with objective measurements of the optimum comfortable on-demand humidification doses.


Eligibility criteria:
inclusion criteria: 1. age \> 18 of age; \< 85 years of age 2. participants with a neuromuscular disorder who: 1. require 24 hour mechanical ventilation in some form through tracheostomy, mask or mouth piece 2. can be ambulatory for at least a few hours during the day while using a heat and moisture exchange device (hme) or no humidification 3. can part of the day use a heated pass-over humidification system while on their ventilator (overnight, for example). 3. able to provide feedback/articulate via some form of communication 4. patients using a trilogy ventilator 5. invasively ventilated patients that are willing to use a hme device on their way to participate in the study (from home to hospital). 6. patients that are willing to participate and are able to consent and sign the informed consent form. (patients with the functional capacity for medical decision-making). exclusion criteria: 1. clinically unstable, i.e., 1. acute respiratory failure 2. participants with refractory hypotension (defined as systolic blood pressure less than 90 mm hg despite inotropic agents) 3. uncontrolled cardiac ischemia or arrhythmias 4. any participant determined as inappropriate for the study by the principal investigator 2. patients suffering from metastatic or terminal cancer 3. patients lacking the functional capacity for medical decision-making.
immune response of caudally administrated tramadol in pediatric lower abdominal surgery

Conditions: Acute Pain

Summary: management of acute pain is one of the most important tasks of perioperative pediatric anesthesia. the alleviation of pain has been defined by the society of pediatric anesthesia, on its 15th annual meeting as a basic human right, irrespective of age, treatment primary service responsible for the patient care. pro-inflammatory cytokines increased by surgical trauma indirectly modulate pain through the release of substances like nitric oxide, oxygen free radicals, prostaglandins, and excitatory amino acids, inducing peripheral and central sensitivity and hyperalgesia. there has been growing interest in determining the possible immune consequences of analgesic administration for the management of postoperative pain

60 children aged 3-10 years undergoing lower abdominal surgery will be randomized into 2 groups (30 patients in each group) to receive caudal block with bupivacaine (0.25%) 1mg/kg (group 1) plus tramadol 1mg/kg (group 2) just after the induction of general anesthesia without premedication. all children will be assessed for the post operative immune response by measuring interleukin 6 and 10 (il-6 and il-10) and tumour necrosing factor-α (tnf-α) using enzyme-linked immunosorbent assay (elisa) technique one hour preoperatively and three hours after incision.

Eligibility criteria:
inclusion criteria: lower abdominal operation exclusion criteria: any systemic disease that might compromise the immune system severe coagulation disorder true allergy to local anesthetics patients with major malformations of the lower spine or meninges any cutaneous or subcutaneous lesion at the site of injection unplanned reoperation, or reoperation within three months diabetes melliutes

Keywords: immune interleukin tramadol postoperartive analgesia pediatric caudal bupivacaine
anrs12373 gundo so - evaluation of an empowerment program for wlhiv in mali

Conditions: HIV Seropositivity; Disclosure; Empowerment; HIV/AIDS

Summary: the objective of this research is to measure the short- and mid-term effects of an empowerment program focused on serostatus disclosure management for women living with hiv (wlhiv) in mali on the "burden of secrecy".

serostatus disclosure is a critical issue for persons living with hiv (plhiv). studies identified numerous benefits associated with disclosure, but various negative consequences have also been documented. gender inequality must be taken into account regarding the disclosure issue, in particular in mali, where women are economically dependent and have a low decision-making power. moreover, in mali, since 2006, plhiv have a legal obligation to disclose their serostatus to their spouse and sexual partner(s) " as soon as possible, or within 6 weeks " after the diagnosis. although this law is not enforced, it highlights the sensitive nature of the serostatus disclosure issue and raise concerns among plhiv and other stakeholders. to support women living with hiv (wlhiv), an empowerment program (gundo-so) was implemented by arcad-sida in mali, in collaboration with several partners. this program aims to empower wlhiv, so that they can make informed decision about disclosing or keeping their serostatus secret in their various life contexts, and that they can identify strategies to disclose or to keep the secret, as well as to manage potential negative reactions. gundo-so ("the room of confidences") was adapted from a program established in quebec and has been implemented in mali. the objective of this research is to measure the short- and mid-term effects of an empowerment program focused on serostatus disclosure management for women living with hiv (wlhiv) in mali on the "burden of secrecy". the evaluation of the effects of the gundo-so program will be helpful to assess the relevance of a national or subregional extension of the program, or even an adaptation to other target populations (e.g. heterosexual men and men who have sex with men living with hiv).

Eligibility criteria:
inclusion criteria: * women living with hiv * living in bamako area (mali) * over 18 years old * knowing their serological status for more than 6 months and less than 5 years * being available to participate in the 9 weekly sessions lasting about 2 hours each. exclusion criteria: * having already participated in gundo-so

Keywords: wlhiv empowerment disclosure mali
clinical analysis of early hormones between patients with traumatic brain injury and cerebral hemorrhage

Conditions: Brain Injury Traumatic Diffuse With Loss of Consciousness

Summary: our understanding of neurosecretory dysfunction after tbi is still insufficient, and the number of patients with neuroendocrine dysfunction caused by craniocerebral trauma may be underestimated, especially the neuroendocrine changes related to hpa axis in the early stage after craniocerebral trauma. moreover, there are few and fragmentary literature data on the benefits of hormone replacement therapy in patients with neuroendocrine disorders after traumatic brain injury. this requires more studies to further determine the characteristics of pituitary function or hormone disorders in the early stage after traumatic brain injury, which makes it necessary for us to further study the neuroendocrine dysfunction (hormone disorder) in the early stage after craniocerebral injury. to explore the relationship between craniocerebral injury and early hormone disorder by measuring the changes of early hormone levels in patients with tbi is of great significance for the early detection of related complications after craniocerebral injury and the evaluation of the prognosis of patients with craniocerebral injury, and can provide a new diagnosis and treatment plan for early intervention of related complications after tbi.


Eligibility criteria:
inclusion criteria: 1. age ≥ 18 years old. 2. the patient was clearly diagnosed as craniocerebral injury. 3. the glasgow score on admission was 3-12 (moderate and severe). 4. it has complete preclinical data. exclusion criteria: 1. complicated with other severe visceral injuries or severe systemic fractures. 2. suffered from craniocerebral tumors, endocrine diseases, cardiovascular diseases, depression, sleep and mental disorders. 3. in the past month, there are people who receive immune and hormone therapy. 4. women during pregnancy and lactation. 5. where there is a logical or common sense error in the data entered. 6. the lack of too much clinical data related to this study.

Keywords: traumatic brain injury cerebral hemorrhage hormone trauma
first line ovarian cancer treatment - cohort study

Conditions: Epithelial Ovarian Cancer

Summary: the french cooperative group gineco proposes to implement an observational study to describe a real situation, in daily practice tolerance and methods of administration of bevacizumab (avastin ®)

population: patients aged 18 years and older with an epithelial ovarian cancer, fallopian tube or primary peritoneal or witch it was decided to initiate a process comprising of bevacizumab (avastin ®) in first-line therapy

Eligibility criteria:
inclusion criteria: * patients aged 18 years and over, * patients with an epithelial ovarian cancer, fallopian tube or peritoneal who will receive bevacizumab (avastin ®) in first-line therapy * patients should be informed of the study orally and should not have any objection their data to be processed. exclusion criteria: * patient participation in a clinical trial * patient non-affiliated to a social security scheme.

Keywords: first line treatment ovarian cancer avastin fallopian tube or primary peritoneal
sonographic assessment of postural lung recruitment in pediatric patients under general anesthesia

Conditions: Collapsed Lung

Summary: anesthesia-induced atelectasis is a well-known entity observed in approximately 68-100% of pediatric patients undergoing general anesthesia. the collapse of dependent lung zones starts with anesthesia induction but can persist for hours or even days after surgery. lung collapse is a pressure-dependent phenomenon. each acinus has a critical closing pressure, i.e., the minimum transpulmonary pressure (ptp) below that the acinus begins to collapse. while airway pressure is homogeneously distributed within all lung units, pleural pressure increases along the vertical gravitational vector because of the lung's weight. as a consequence, the decreased ptp in the dependent zones promotes collapse. this means that patients in the supine position suffer from increasing closing pressures in the ventral to dorsal direction. alveolar recruitment maneuvers recruit collapsed alveoli, increase gas exchange, and improve arterial oxygenation. the investigators hypothesized that in children with anesthesia-induced atelectasis, postural changes have recruiting effects and improve lung aeration assessed by lung ultrasound.

compare lung aeration between two different lung recruitment strategies (recruitment maneuvers in supine position and recruitment maneuvers with postural changes of lateral decubitus with 10 cmh2o level of positive-end expiratory pressure (peep) during 180 seconds; in pediatric patients scheduled for surgery under general anesthesia using ultrasound imaging and a four-point-aeration score to assess the lung aeration.

Eligibility criteria:
inclusion criteria: * written informed consent by parents. * patients aged 6 months to 5 years old * scheduled for surgery under general anesthesia with tracheal intubation with atelectasis assessed by lung ultrasound after anesthesia induction. * american society of anesthesiologists classification: physical status i-ii exclusion criteria: * acute airway infection * cardiovascular or pulmonary disease * previous thoracic procedure

Keywords: lung ultrasound recruitment maneuver atelectasis children